TILS.L Share News (TILS)
TILS Share
TILS Share
TILS Share
TILS Share
TILS
TILS Share
TILS Broker
TILS Directors
TILS Financial
TILS
TILS Short
TILS
(Sharecast News) - Biotechnology company Tiziana Life Sciences has filed a provisional patent application on the combination of nanoparticle-Actinomycin D (NP-ACT D) with anti-interleukin-6 receptor monoclonal antibody (anti-IL-6R), it announced on Monday, as a potential therapy for the management of Covid-19 disease.
Read more
Tiziana Life Sciences Acquires Potential Covid-19 Treatment Medication
Read moreUK WINNERS & LOSERS SUMMARY: Lockdowns Lift Just Eat Takeaway Orders
Read moreTiziana Life Sciences Shares Double On Covid-19 Treatment News
Read moreLONDON BRIEFING: Bank Of England Extends UK Government's Overdraft
Read moreTiziana Raises USD10 Million To Help Fund Covid-19 Drug Development
Read moreTiziana Secures USD10 Million To Help Coronavirus Antibody Development
Read more(Sharecast News) - Tiziana Life Sciences said on Wednesday that it is expediting the development of a drug that could help in the treatment of people infected with Covid-19.
Read moreTiziana Shares Skyrocket On Expedited Covid-19 Treatment Development
Read moreTiziana Life Sciences Proposes ADS Offering On Nasdaq
Read moreDIRECTOR DEALINGS SUMMARY: Biffa Municipal MD Sells 154,000 Shares
Read moreTiziana Life Sciences Hires OKYO Pharma Director MacRae As Non-Exec
Read moreDIRECTOR DEALINGS: Tiziana Life Says Associate Of Chair Bought Shares
Read moreTiziana Life Science To Cancel AIM Trading Ahead Of Move To Bermuda
Read moreTiziana Says Antibody Foralumab "Well Tolerated" At All Doses Tested
Read more